China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek Biotechnology Co., Ltd., a fellow Chinese biotech firm, for the latter’s Category 1 drug MG-K10. This marks CMS’s second major licensing deal in less than a month. Financial details of the agreement were not disclosed. Under the terms, CMS will obtain co-development and exclusive commercialization rights for MG-K10 in mainland China, Hong Kong, Macau, Taiwan, and Singapore. MabGeek will collaborate on commercial activities and will be responsible for selling and supplying the product.
MG-K10: A Promising Anti-IL-4Rα Antibody
MG-K10 is an anti-IL-4Rα antibody that inhibits both IL-4 and IL-13 signaling pathways. It is designed to be a best-in-class drug with a monthly administration schedule, offering a favorable efficacy and safety profile. The initial indication for MG-K10 is atopic dermatitis (AD), a chronic inflammatory skin condition with significant unmet medical needs. The drug’s potential to provide long-term symptom control with less frequent dosing makes it an attractive candidate for patients and healthcare providers alike.
Strategic Partnership for Regional Expansion
This partnership between CMS and MabGeek underscores the growing trend of collaboration within China’s biotech sector. CMS’s strong commercial presence in Greater China and Singapore will be instrumental in accelerating the development and market penetration of MG-K10. Meanwhile, MabGeek’s expertise in biotechnology research and development will ensure the drug’s scientific advancement. Together, the two companies aim to bring innovative treatment options to patients suffering from atopic dermatitis and other potential indications in the future.-Fineline Info & Tech
